EPA:GNFT Genfit (GNFT) Stock Price, News & Analysis €3.87 0.00 (0.00%) As of 05/26/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Genfit Stock (EPA:GNFT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genfit alerts:Sign Up Key Stats Today's Range€3.85▼€3.9450-Day Range€2.90▼€4.1252-Week Range N/AVolume165,405 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More… Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Stock News HeadlinesGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in ItalyMay 21, 2025 | morningstar.comEuropean Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday TradingApril 23, 2025 | msn.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 27, 2025 | Crypto 101 Media (Ad)Guggenheim Reaffirms Their Buy Rating on Genfit (GNFTF)March 31, 2025 | markets.businessinsider.comGENFIT S.A.: GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 21, 2025 | finanznachrichten.deEuropean Equities Traded in the US as American Depositary Receipts Surge Higher in Monday TradingMarch 3, 2025 | msn.comGenfit reports preliminary results of repurchase offer to 2025 OCEANEs holdersFebruary 21, 2025 | msn.comGENFIT S.A.: GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs HoldersFebruary 10, 2025 | finanznachrichten.deSee More Headlines GNFT Stock Analysis - Frequently Asked Questions How have GNFT shares performed this year? Genfit's stock was trading at €3.54 at the beginning of the year. Since then, GNFT stock has increased by 9.4% and is now trading at €3.87. View the best growth stocks for 2025 here. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Advanced Micro Devices (AMD), Alibaba Group (BABA), FedEx (FDX), GameStop (GME), NightHawk Biosciences (NHWK), Nikola (NKLA) and United Parcel Service (UPS). Industry, Sector and Symbol Stock ExchangeEPA SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolEPA:GNFT CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (EPA:GNFT) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.